On October 2, CANSINOBIO fell 5.58% in regular trading, trading at 35.12 HKD/share, with turnover of approximately 15.37 million HKD. The decline came after the stock surged over 30% across three consecutive trading sessions, triggering an abnormal stock trading alert under Shanghai Stock Exchange rules.

The company issued an announcement emphasizing that no material information exists that should have been but has not been disclosed, and that directors and senior management did not trade company shares during the abnormal fluctuation period. The preceding rally was primarily driven by Moderna's announcement that its co-developed personalized mRNA neoantigen therapy with Merck would be presented at the ESMO congress in Madrid, combined with CANSINOBIO's strategic cooperation agreement with deepGeneAI to jointly develop personalized mRNA therapeutic cancer vaccines targeting gastrointestinal solid tumors and rare cancers.

The broader biotechnology sector was under significant pressure, with BEONE MEDICINES down 6.65%, INNOVENT BIO down 4.79%, AKESO down 4.23%, 3SBIO down 5.91%, and SKB BIO down 5.54%, reflecting broad-based short-term profit-taking across the sector.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)